Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: Results of CALGB study 10001 (alliance)

Haematologica

Volumn 99, Issue 1, 2014, Pages 111-115

  Wetzler, Meir ^a   Watson, Dorothy ^b   Stock, Wendy ^c   Koval, Gregory ^c   Mulkey, Flora A ^b   Hoke, Eva E ^b   McCarty, John M ^d   Blum, William G ^e   Powell, Bayard L ^f   Marcucci, Guido ^e   Bloomfield, Clara D ^e   Linker, Charles A ^g   Larson, Richard A ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84892587460     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.085811     Document Type: Article

References (23)

1. Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer. 2011;117(8):1583-1594.
2. Wetzler M, Dodge RK, Mrozek K, Stewart CC, Carroll AJ, Tantravahi R, et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol. 2004;124(3):275-288.
3. Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, et al. Quantitative realtime RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006;28(5):1099-1103.
4. Soverini S, Martinelli G, Amabile M, Poerio A, Bianchini M, Rosti G, et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem. 2004;50(7):1205-1213.
5. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lym-phoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85(8):2025-2037.
6. Kalbfleisch JD, Pentice RL. The statistical analysis of failure time data. 2nd Edition ed: Wiley-interscience, 2002.
7. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
8. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.
9. Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi R, Block AW, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999;93(11):3983-3993.
10. Mizuta S, Matsuo K, Yagasaki F, Yujiri T, Hatta Y, Kimura Y, et al. Pre-transplant ima-tinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia. 2011;25(1):41-47.
11. Blume KG, Forman SJ, O'Donnell MR, Doroshow JH, Krance RA, Nademanee AP, et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood. 1987;69(4):1015-1020.
12. Marks DI, Forman SJ, Blume KG, Perez WS, Weisdorf DJ, Keating A, et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant. 2006;12(4):438-453.
13. Koval G, Wetzler M, Watson D, Owzar K, Bloomfield CD, Malnassy G, et al. Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001. ASH Annual Meeting Abstracts. 2011;118(21):2541.
14. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lym-phoblastic leukemia (ALL) the greatest benefit is achieved from a matched sibling allo-geneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy in All patients: final results of the international ALL trial (MRC UKALL XII/ ECOG E2993). Blood. 2008;111(4):1827-1833.
15. Shin HJ, Chung JS, Cho GJ. Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autolo-gous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 2005;36(10):917-918.
16. Ribera JM, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95(1):87-95.
17. Tanguy-Schmidt A, de Labarthe A, Rousselot P, Huguet F, Delabesse E, Witz F, et al. Long-Term Results of the Imatinib GRAAPH-2003 Study in Newly-Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. ASH Annual Meeting Abstracts. 2009;114(22):3080.
18. Linker C, Damon L, Martin T, Blume K, Forman S, Snyder D, et al. Autologous hematopoietic cell transplantation for high-risk ALL. Bone Marrow Transplant. 2011;46(3):460-461.
19. Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28(22):3644-3652.
20. Giebel S, Labopin M, Gorin NC, Caillot D, Leguay T, Schaap N, et al. Autologous HSCT for Ph-Positive Adult Acute Lymphoblastic Leukemia: A Curative Option in the Era of Tyrosine Kinase Inhibitors? an Analysis From the Acute Leukemia Working Party of the EBMT. ASH Annual Meeting Abstracts. 2012;120(21):233.
21. Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521-6528.
22. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116(12):2070-2077.
23. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004;36(5):453-461.